Clinical Burden and Unmet Need in Recurrent Pericarditis: A Systematic Literature Review.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
Historique:
pubmed:
22
9
2020
medline:
9
2
2022
entrez:
21
9
2020
Statut:
ppublish
Résumé
Inflammation of the pericardium (pericarditis) is characterized by excruciating chest pain. This systematic literature review summarizes clinical, humanistic, and economic burdens in acute, especially recurrent, pericarditis, with a secondary aim of understanding United States treatment patterns and outcomes. Short-term clinical burden is well characterized, but long-term data are limited. Some studies report healthcare resource utilization and economic impact; none measure health-related quality-of-life. Pericarditis is associated with infrequent but potentially life-threatening complications, including cardiac tamponade (weighted average: 12.7% across 10 studies), constrictive pericarditis (1.84%; 9 studies), and pericardial effusion (54.7%; 16 studies). There are no approved pericarditis treatments; treatment guidelines, when available, are inconsistent on treatment course or duration. Most recommend first-line use of conventional treatments, for example, nonsteroidal antiinflammatory drugs with or without colchicine; however, 15-30% of patients experience recurrence. Second-line therapy may involve conventional therapies plus long-term utilization of corticosteroids, despite safety issues and the difficulty of tapering or discontinuation. Other exploratory therapies (eg, azathioprine, immunoglobulin, methotrexate, anakinra) present steroid-sparing options, but none are supported by robust clinical evidence, and some present tolerability challenges that may impact adherence. Pericardiectomy is occasionally pursued in treatment-refractory patients, although data are limited. This lack of an evidence-based treatment pathway for patients with recurrent disease is reflected in readmission rates, for example, 12.2% at 30 days in 1 US study. Patients with continued recurrence and inadequate treatment response need approved, safe, accessible treatments to resolve pericarditis symptoms and reduce recurrence risk without excessive treatment burden.
Identifiants
pubmed: 32956167
pii: 00045415-202203000-00002
doi: 10.1097/CRD.0000000000000356
pmc: PMC8812421
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-69Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Disclosure: Dr Al.K. receives research grant from scientific advisory board Kiniksa Pharmaceuticals Corp. and advisory board Swedish Orphan Dr. A.K. Biovitrum AB, advisory board Pfizer, Inc. Dr P.C. receives advisory board Swedish Orphan Biovitrum AB and advisory board Kiniksa Pharmaceuticals Corp. Dr. A.K. is the consultant and received honoraria from Novartis, Lilly, Kiniksa, within the past 12 months. A.F. and C.C. are the employees (AF current, CC former) of Purple Squirrel Economics, which acted as paid consultants to Kiniksa Pharmaceuticals Corp. M.L.-W. and M.M. are employees of Kiniksa Pharmaceuticals Corp. Dr M.F. declares no conflict of interest.
Références
Tingle LE, Molina D, Calvert CW. Acute pericarditis. Am Fam Physician. 2007;76:1509–1514.
Adler Y, Charron P, Imazio M, et al.; ESC Scientific Document Group. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36:2921–2964.
Cremer PC, Kumar A, Kontzias A, et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68:2311–2328.
Imazio M, Cecchi E, Demichelis B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart. 2008;94:498–501.
Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130:1601–1606.
Kumar N, Pandey A, Jain P, et al. Acute pericarditis-associated hospitalization in the USA: a nationwide analysis, 2003-2012. Cardiology. 2016;135:27–35.
Adler Y, Imazio M. Recurrent pericarditis—UpToDate. Available at: https://www.uptodate.com/contents/recurrent-pericarditis/print . Accessed December 23, 2019.
Fardman A, Charron P, Imazio M, et al. European guidelines on pericardial diseases: a focused review of novel aspects. Curr Cardiol Rep. 2016;18:46.
Soler-Soler J. Relapsing pericarditis. Heart. 2004;90:1364–1368.
Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart. 2015;101:1159–1168.
Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115:2739–2744.
Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. Chicester, United Kingdom: John Wiley & Sons; 2019. Available at: https://training.cochrane.org/handbook/current . Accessed December 23, 2019.
Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. Available at: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf . Accessed December 23, 2019.
National Institute for Health and Care Excellence. Methods for the Development of NICE Public Health Guidance. 3rd ed. London, United Kingdom; 2012. Available at: https://www.ncbi.nlm.nih.gov/books/NBK395862/pdf/Bookshelf_NBK395862.pdf . Accessed December 23, 2019.
Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Centre for Evidence-Based Medicine. Oxford Centre for Evidence-based Medicine—Levels of Evidence (March 2009). Available at: https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ . Accessed December 23, 2019.
Furqan M, Abdullah R, Verma B, et al. Effect of anakinra on colchicine resistant and steroid dependent recurrent pericarditis: a systemic review and meta-analysis. J Am Coll Cardiol. 2019;73:1017.
Lutschinger LL, Rigopoulos AG, Schlattmann P, et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovasc Disord. 2019;19:207.
Imazio M, Brucato A, Cemin R, et al.; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409–414.
Imazio M, Brucato A, Cemin R, et al.; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369:1522–1528.
Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–2237.
Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165:1987–1991.
Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis. Circulation. 2005;112:2012–2016.
Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316:1906–1912.
Crotty C, Forsythe A, Magestro M. PCV9: unmet needs & burden of recurrent pericarditis (RP): results of a systematic literature review (SLR). Value in Health. 2019;22:S119.
Brucato A, Brambilla G, Moreo A, et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol. 2006;98:267–271.
Vassilopoulos D, Vasileiou P, Koutsianas C, et al. Anakinra for the Management of Resistant Idiopathic Recurrent Pericarditis in Adults—ACR Meeting Abstracts. Available at: https://acrabstracts.org/abstract/anakinra-for-the-management-of-resistant-idiopathic-recurrent-pericarditis-in-adults/ . Accessed December 23, 2019.
Ratnapalan S, Brown K, Benson L. Children presenting with acute pericarditis to the emergency department. Pediatr Emerg Care. 2011;27:581–585.
Shakti D, Hehn R, Gauvreau K, et al. Idiopathic pericarditis and pericardial effusion in children: contemporary epidemiology and management. J Am Heart Assoc. 2014;3:e001483.
Imazio M, Brucato A, Pluymaekers N, et al. Recurrent pericarditis in children and adolescents: a multicentre cohort study. J Cardiovasc Med (Hagerstown). 2016;17:707–712.
Baskar S, Betancor J, Patel K, et al. Cardiac MRI in evaluation and management of pediatric pericarditis. Prog Pediatr Cardiol. 2018;50:39–45.
Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol. 2004;43:1042–1046.
Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis. Circulation. 2008;118:667–671.
Artom G, Koren-Morag N, Spodick DH, et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J. 2005;26:723–727.
Imazio M, Demichelis B, Parrini I, et al. Management, risk factors, and outcomes in recurrent pericarditis. Am J Cardiol. 2005;96:736–739.
Arguero V, Sanchez A. Management and Treatment of Acute Pericarditis in the Emergency Room. Available at: https://esc365.escardio.org/Congress/Acute-Cardiovascular-Care-2018/Poster-Session-5-Pulmonary-embolism-Arrhythmias-and-Sudden-Cardiac-Death-Im/168321-management-and-treatment-of-acute-pericarditis-in-the-emergency-room#abstract . Accessed December 23, 2019.
Lazaros G, Vasileiou P, Koutsianas C, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014;73:2215–2217.
Alraies MC, AlJaroudi W, Yarmohammadi H, et al. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am J Cardiol. 2015;115:542–547.
Jain S, Thongprayoon C, Espinosa RE, et al. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015;116:1277–1279.
Finetti M, Insalaco A, Cantarini L, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr. 2014;164:1425.e1–1431.e1.
Imazio M, Lazaros G, Maestroni S, et al. Anakinra for Recurrent Pericarditis: Results from a Real World European Registry. Available at: https://esc365.escardio.org/Congress/ESC-Congress-2018/Best-Posters-6-Best-Posters-in-pericardial-disease/176302-anakinra-for-recurrent-pericarditis-results-from-a-real-world-european-registry-beat-registry . Accessed December 23, 2019.
Mendel A, Mardigyan V. Anakinra for treatment of severe idiopathic pericarditis: experience in a series of seven patients. J Rheumatol. 2017;44: 854.
Antonatou K, Vasileiou P, Koutsianas C, et al. FRI0496 Long term safety and efficacy of anakinra in adult patients with refractory recurrent idiopathic pericarditis. Ann Rheum Dis. 2016;75:618.
Brown A, Liu X, Chatterjee S. Azathioprine may be an Effective Steroid Sparing Agent in Patients with Isolated Recurrent Pericarditis—ACR Meeting Abstracts. Available at: https://acrabstracts.org/abstract/azathioprine-may-be-an-effective-steroid-sparing-agent-in-patients-with-isolated-recurrent-pericarditis/ . Accessed December 23, 2019.
Vianello F, Cinetto F, Cavraro M, et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol. 2011;147:477–478.
Moretti M, Buiatti A, Merlo M, et al. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis. Am J Cardiol. 2013;112:1493–1498.
Thompson JL, Burkhart HM, Dearani JA, et al. Pericardiectomy for pericarditis in the pediatric population. Ann Thorac Surg. 2009;88:1546–1550.
Mody P, Bikdeli B, Wang Y, et al. Trends in acute pericarditis hospitalizations and outcomes among the elderly in the USA, 1999-2012. Eur Heart J Qual Care Clin Outcomes. 2018;4:98–105.
Sud K, Sabharwal B, Wei X, et al. In-hospital outcomes and etiologies for 30-day readmissions in patients with acute pericarditis. J Am Coll Cardiol. 2018;71:A786.
Lattuca B, Khoueiry Z, Leclercq F, et al. 090: Could heart rate predict duration of hospitalizations for patients admitted for acute pericarditis? Arch Cardiovasc Dis Suppl. 2013;5:29.
Klein A, Cremer P, Kontzias A, et al. Recurrent Pericarditis Epidemiology in the United States (2013-2018). Pasadena, CA: American College of Epidemiology; 2019.
Lador A, Hasdai D, Mager A, et al. Incidence and prognosis of pericarditis after ST-elevation myocardial infarction (from the Acute Coronary Syndrome Israeli Survey 2000 to 2013 Registry Database). Am J Cardiol. 2018;121:690–694.
Sigvardt FL, Hansen ML, Kristensen SL, et al. 5036: Increased 1-year mortality among patients discharged following hospitalization for pericarditis—a nationwide cohort study. Eur Heart J. 2019;40:ehz746.0039.
Søgaard KK, Sørensen HT, Smeeth L, et al. Acute pericarditis and cancer risk: a matched cohort study using linked UK primary and secondary care data. J Am Heart Assoc. 2018;7:e009428.
Verma B, Sato K. Pericardial effusion: a reliable imaging indicator of underlying inflammation in recurrent pericarditis. J Am Soc Echocardiogr. 2018;31:B85.
Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124:1270–1275.
Stewart S, Yang KCK, Atkins K, et al. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22:28.
Imazio M, Lazaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med (Hagerstown). 2016;17:263–269.
Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118–1125.
Gopaldas RR, Dao TK, Caron NR, et al. Predictors of in-hospital complications after pericardiectomy: a nationwide outcomes study. J Thorac Cardiovasc Surg. 2013;145:1227–1233.
Gillaspie EA, Stulak JM, Daly RC, et al. A 20-year experience with isolated pericardiectomy: analysis of indications and outcomes. J Thorac Cardiovasc Surg. 2016;152:448–458.
Picco P, Brisca G, Traverso F, et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 2009;60:264–268.
Brucato A, Imazio M, Cremer PC, et al. Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. Intern Emerg Med. 2018;13:839–844.